Ikena Oncology Inc (NASDAQ:IKNA) — Market Cap & Net Worth
Market Cap & Net Worth: Ikena Oncology Inc (IKNA)
Ikena Oncology Inc (NASDAQ:IKNA) has a market capitalization of $59.90 Million ($59.90 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21193 globally and #4532 in its home market, demonstrating a 13.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ikena Oncology Inc's stock price $1.43 by its total outstanding shares 41889500 (41.89 Million). Analyse Ikena Oncology Inc cash flow conversion to see how efficiently the company converts income to cash.
Ikena Oncology Inc Market Cap History: 2021 to 2025
Ikena Oncology Inc's market capitalization history from 2021 to 2025. Data shows change from $525.29 Million to $59.90 Million (-51.18% CAGR).
Index Memberships
Ikena Oncology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #607 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2046 of 3165 |
Weight: Ikena Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ikena Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ikena Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.01x
Ikena Oncology Inc's market cap is 9.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $525.29 Million | $30.98 Million | -$34.12 Million | 16.95x | N/A |
| 2022 | $111.43 Million | $15.62 Million | -$68.77 Million | 7.13x | N/A |
| 2023 | $82.52 Million | $9.16 Million | -$68.17 Million | 9.01x | N/A |
Competitor Companies of IKNA by Market Capitalization
Companies near Ikena Oncology Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Ikena Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Ikena Oncology Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Ikena Oncology Inc's market cap moved from $525.29 Million to $ 59.90 Million, with a yearly change of -51.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $59.90 Million | -12.80% |
| 2024 | $68.70 Million | -16.75% |
| 2023 | $82.52 Million | -25.94% |
| 2022 | $111.43 Million | -78.79% |
| 2021 | $525.29 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Ikena Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.90 Million USD |
| MoneyControl | $59.90 Million USD |
| MarketWatch | $59.90 Million USD |
| marketcap.company | $59.90 Million USD |
| Reuters | $59.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more